Abstract Number: 2793 • 2014 ACR/ARHP Annual Meeting
BMP2 Requires TGF-Beta to Induce Osteophytes during Experimental Osteoarthritis
Background/Purpose: Osteophytes are a major hallmark of osteoarthritis (OA). Both TGF-beta and BMP2 can induce osteophytes in murine knee joints. We demonstrated that TGF-beta could…Abstract Number: 2754 • 2014 ACR/ARHP Annual Meeting
Predictors of Quality of Life in Behçet’s Syndrome
Background/Purpose: Quality of life is commonly impaired in patients with chronic inflammatory diseases. The disease itself as well as the drugs used may be responsible…Abstract Number: 2755 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Quality of Life in BEHÇET’S Disease: The Role of Patients Reportedoutcomes
Background/Purpose Behçet’s disease (BD) is a systemic vasculitis, typically characterised by recurrent oro-genital ulcers, ocular inflammation and skin manifestations; articular, vascular, gastro-enteric and neurological involvement…Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…Abstract Number: 2758 • 2014 ACR/ARHP Annual Meeting
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
Background/Purpose: To identify the clinical factors predicting a good clinical response to Infliximab (IFX) therapy after 12 months in patients with Behçet’s disease (BD) refractory…Abstract Number: 2759 • 2014 ACR/ARHP Annual Meeting
Anti-TNF Treatment for Refractory Vascular Involvement of Behçet’s Syndrome
Background/Purpose: The optimal management of major vascular involvement in patients with Behçet’s syndrome (BS) is still a challenge. Methods: We reviewed the charts of 16…Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…Abstract Number: 2761 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Parenchymal Neurological Involvement in Behcet’s Syndrome Patients with Panuveitis
Background/Purpose Behcet’s Syndrome (BS) is a systemic vasculitis which may involve multiple organ systems simultaneously. Most frequently, clinical findings in BS fit into well recognized…Abstract Number: 2762 • 2014 ACR/ARHP Annual Meeting
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
Background/Purpose: Central nervous system involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB)…Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…Abstract Number: 2764 • 2014 ACR/ARHP Annual Meeting
S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes
Background/Purpose: Reversible Cerebral Vasoconstriction Syndromes (RCVS) are a group of disorders characterized by acute onset of recurrent thunderclap headaches with or without neurologic deficits. Radiologically,…Abstract Number: 2765 • 2014 ACR/ARHP Annual Meeting
Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome
Putative blood biomarkers of Reversible Cerebral Vasoconstriction Syndrome Background/Purpose The pathophysiology and molecular mechanisms of Reversible Cerebral Vasoconstriction Syndrome (RCVS) are unknown. Objective of the…Abstract Number: 2766 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil in the Treatment of Primary Central Nervous System Vasculitis
Background/Purpose . The optimal management of primary central nervous system vasculitis (PCNSV) remains unclear. Cyclophosphamyde (CYC) in combination with glucocorticoids (GCs) or GCs alone are…Abstract Number: 2767 • 2014 ACR/ARHP Annual Meeting
Core Outcome Domains and Potential Measurement Instruments in polymyalgia Rheumatica (PMR) Using Omeract Filter 2.0
Background/Purpose The OMERACT PMR specialist interest group was established to develop a core outcome measurement set for PMR using the methods of OMERACT filter 2.0.…
ACR Meeting Abstracts